These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 14517521)

  • 1. Effect of corticosteroids in addition to intravenous gamma globulin therapy on serum cytokine levels in the acute phase of Kawasaki disease in children.
    Okada Y; Shinohara M; Kobayashi T; Inoue Y; Tomomasa T; Kobayashi T; Morikawa A;
    J Pediatr; 2003 Sep; 143(3):363-7. PubMed ID: 14517521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective high dose gamma-globulin treatment in Kawasaki disease: assessment of clinical aspects and cost effectiveness.
    Sato N; Sugimura T; Akagi T; Yamakawa R; Hashino K; Eto G; Iemura M; Ishii M; Kato H
    Pediatr Int; 1999 Feb; 41(1):1-7. PubMed ID: 10200128
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A multicenter prospective randomized trial of corticosteroids in primary therapy for Kawasaki disease: clinical course and coronary artery outcome.
    Inoue Y; Okada Y; Shinohara M; Kobayashi T; Kobayashi T; Tomomasa T; Takeuchi K; Morikawa A
    J Pediatr; 2006 Sep; 149(3):336-341. PubMed ID: 16939743
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome.
    Newburger JW; Takahashi M; Beiser AS; Burns JC; Bastian J; Chung KJ; Colan SD; Duffy CE; Fulton DR; Glode MP
    N Engl J Med; 1991 Jun; 324(23):1633-9. PubMed ID: 1709446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytokine modulation with immune gamma-globulin in peripheral blood of normal children and its implications in Kawasaki disease treatment.
    Gupta M; Noel GJ; Schaefer M; Friedman D; Bussel J; Johann-Liang R
    J Clin Immunol; 2001 May; 21(3):193-9. PubMed ID: 11403226
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Corticosteroids in the treatment of the acute phase of Kawasaki disease.
    Shinohara M; Sone K; Tomomasa T; Morikawa A
    J Pediatr; 1999 Oct; 135(4):465-9. PubMed ID: 10518080
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Do cytokines correlate with refractory Kawasaki disease in children?
    Wang Y; Qian SY; Yuan Y; Wang Q; Gao L; Chen X; Yu X; Zhen Z
    Clin Chim Acta; 2020 Jul; 506():222-227. PubMed ID: 32156603
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dramatic decrease of circulating levels of monocyte chemoattractant protein-1 in Kawasaki disease after gamma globulin treatment.
    Terai M; Jibiki T; Harada A; Terashima Y; Yasukawa K; Tateno S; Hamada H; Oana S; Niimi H; Matsushima K
    J Leukoc Biol; 1999 May; 65(5):566-72. PubMed ID: 10331483
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effects of three intravenous gamma globulin regimens on Kawasaki disease and relevant coronary complication rates in pediatric patients: a comparative study].
    DU ZD; Zhao D; DU JB; Lu S; Yi JM; Hou AC; Zhou ZS; Ding GF;
    Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(44):3119-21. PubMed ID: 18269869
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of intravenous immune globulin therapy combined with dexamethasone for the initial treatment of acute Kawasaki disease.
    Jibiki T; Terai M; Kurosaki T; Nakajima H; Suzuki K; Inomata H; Terashima I; Honda T; Yasukawa K; Hamada H; Kohno Y
    Eur J Pediatr; 2004 Apr; 163(4-5):229-33. PubMed ID: 14963702
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early treatment with intravenous immunoglobulin in patients with Kawasaki disease.
    Tse SM; Silverman ED; McCrindle BW; Yeung RS
    J Pediatr; 2002 Apr; 140(4):450-5. PubMed ID: 12006960
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aberrantly decreased levels of NKG2D expression in children with kawasaki disease.
    Ge X; Li CR; Yang J; Wang GB
    Scand J Immunol; 2013 May; 77(5):389-97. PubMed ID: 23298273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial.
    Kobayashi T; Saji T; Otani T; Takeuchi K; Nakamura T; Arakawa H; Kato T; Hara T; Hamaoka K; Ogawa S; Miura M; Nomura Y; Fuse S; Ichida F; Seki M; Fukazawa R; Ogawa C; Furuno K; Tokunaga H; Takatsuki S; Hara S; Morikawa A;
    Lancet; 2012 Apr; 379(9826):1613-20. PubMed ID: 22405251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Serum levels of interleukin-38 and interleukin-1β in the acute phase of Kawasaki disease in children].
    Zhang XY; He T; Ling JY; Hu XF; Wen Y; Wei J; Lu HL
    Zhongguo Dang Dai Er Ke Za Zhi; 2018 Jul; 20(7):543-548. PubMed ID: 30022755
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravenous immune globulin plus corticosteroids in refractory Kawasaki disease.
    Jibiki T; Kato I; Shiohama T; Abe K; Anzai S; Takeda N; Yamaguchi KI; Kanazawa M; Kurosaki T
    Pediatr Int; 2011 Oct; 53(5):729-735. PubMed ID: 21342358
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted use of prednisolone with the second IVIG dose for refractory Kawasaki disease.
    Kimura M; Harazaki M; Fukuoka T; Asakura I; Sakai H; Kamimaki T; Ohkawara I; Akiyama N; Tsurui S; Iwashima S; Shimomura M; Morishita H; Meguro T; Seto S
    Pediatr Int; 2017 Apr; 59(4):397-403. PubMed ID: 27743415
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Coronary risk factors in acute Kawasaki disease: correlation of serum immunoglobulin levels with coronary complications.
    Sawaji Y; Haneda N; Yamaguchi S; Kajino Y; Kishida K; Seto S; Konishi N; Waki K; Baba K; Arisawa K; Kamiya T; Mori C
    Acta Paediatr Jpn; 1998 Jun; 40(3):218-25. PubMed ID: 9695293
    [TBL] [Abstract][Full Text] [Related]  

  • 18. American Academy of Pediatrics, Committee on Infectious Diseases: Intravenous gamma-globulin use in children with Kawasaki disease.
    Pediatrics; 1988 Jul; 82(1):122. PubMed ID: 2454444
    [No Abstract]   [Full Text] [Related]  

  • 19. Kawasaki disease shock syndrome: clinical characteristics and possible use of IL-6, IL-10 and IFN-γ as biomarkers for early recognition.
    Li Y; Zheng Q; Zou L; Wu J; Guo L; Teng L; Zheng R; Jung LKL; Lu M
    Pediatr Rheumatol Online J; 2019 Jan; 17(1):1. PubMed ID: 30611297
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Th17- and Treg-related cytokine and mRNA expression are associated with acute and resolving Kawasaki disease.
    Guo MM; Tseng WN; Ko CH; Pan HM; Hsieh KS; Kuo HC
    Allergy; 2015 Mar; 70(3):310-8. PubMed ID: 25585854
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.